Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.94 |
| ▸ | PRKCG | P05129 | 5/20 | 0.91 |
| ▸ | PRKCB | P05771 | 5/20 | 0.91 |
| ▸ | PRKCH | P24723 | 5/20 | 0.91 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.91 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.91 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.91 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.91 |
| ▸ | PRKCI | P41743 | 4/20 | 0.91 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.91 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.91 |
| ▸ | USP2 | O75604 | 2/20 | 0.91 |
| ▸ | TP53 | P04637 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295345 | 1.00 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL1568997 | 1.00 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL2411275 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL31109155 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18399995 | 0.99 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL1893793 | 0.95 | PRKCA (0.89) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL6844180 | 0.95 | PRKCA (0.89) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL19271683 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL115567 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| Phorbol Myristate Acetate SCHEMBL22736719 | 0.95 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703741-B2 | Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan | MESTEX AG (CH) | 2014-04-22 | — | — | US | claimed |
| US-20080153780-A1 | Use Of A Vanilloid Receptor Agonist Together With A Glycosaminoglycan Or Proteoglycan For Producing An Agent For Treating Articular Pains And Method For Applying Said Agent | MESTEX AG (CH) | 2008-06-26 | — | — | US | claimed |
| US-20170112787-A1 | METHODS OF TREATMENT OF INFLAMMATION OF THE GUT | THE UNIVERSITY OF CONNECTICUT | 2017-04-27 | — | — | US | disclosed |
| US-8703741-B2 | Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan | MESTEX AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20100047181-A1 | MIXTURE OF A VANILLOID RECEPTOR AGONIST AND A SUBSTANCE INHIBITING NERVE REGENERATION, USE THEREOF FOR PRODUCING A PAINKILLER, AND METHOD FOR APPLYING SAID PAINKILLER | MESTEX AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20080153780-A1 | Use Of A Vanilloid Receptor Agonist Together With A Glycosaminoglycan Or Proteoglycan For Producing An Agent For Treating Articular Pains And Method For Applying Said Agent | MESTEX AG (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112787-A1 | METHODS OF TREATMENT OF INFLAMMATION OF THE GUT | CNR2, CNR1, GPR18 | PRKCA 3530/4885PRKCG 3405/4885PRKCB 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.